This Poster presentation is under embargo until 17 September 2026, as per congress regulations.

Please subscribe using the button below to receive a notification when the material becomes available:

Register for email alerts

 

 

Publication
  • EULAR •
  • 5 June, 2026 •
  • •

Updated exposure–safety analysis of emapalumab in patients with macrophage activation syndrome (MAS)

Rafael Krmar, Brian Jamieson, Fabrizio De Benedetti, Alexei A. Grom, Axel Facius, Patrick Brossard

Available materials

Poster
Publication
  • EULAR •
  • 5 June, 2026 •
  • •

Updated population pharmacokinetic (popPK) model for emapalumab using data from four prospective clinical trials in patients with hemophagocytic lymphohistiocytosis/macrophage activation syndrome (MAS)

Patrick Brossard, Axel Facius, Brian Jamieson

Available materials

Poster
Publication
  • CCR East •
  • 1 May, 2026 •
  • •

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Edward M. Behrens, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullman, Adnan Mahmood, Andrew Danquah, Elena Burillo, Steve Mallett, Brian D. Jamieson, Alexei A. Grom, Fabrizio De Benedetti

Available materials

Poster
Publication
  • CCR East •
  • 1 May, 2026 •
  • •

Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Alexei A. Grom, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Edward M. Behrens, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullman, Adnan Mahmood, Andrew Danquah, Elena Burillo, Steve Mallett, Brian D. Jamieson, Fabrizio De Benedetti

Available materials

Poster
Sign up for alerts